Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with a specific transaction date of July 7, 2022. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific insider transaction rather than a financial results report.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $43.3200 per ADS |
| Volume | 1,189.015 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a single acquisition event within an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed as an acquisition of notional ADSs within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: This was an initial notification of an acquisition, not a sale.
- Market Price: The shares were acquired at $43.32 on the NYSE.
- Financial Data: No company-wide financial performance data is included in this specific filing.